May 2009
ECO Animal Health Group plc
Further re: Aivlosin® research
Dr David Brown and his team at the Virology Division of the Department of
Pathology at the University of Cambridge have been awarded a grant of £500,000
by the Medical Research Council to investigate the inhibition of influenza
viruses by macrolide antibiotics.
During earlier studies funded by Eco Animal Health (Eco), it has been discovered
that Aivlosin®, Eco's patented macrolide antibiotic, appears to prevent the
replication of certain common viruses including influenza in laboratory test
systems without damaging cell cultures.
Eco and the University of Cambridge entered a collaborative research agreement
in 2006 to investigate these new potential indications for Aivlosin® which is
currently licensed for respiratory and enteric bacterial diseases in pigs and
poultry.
These unexpected findings have formed the basis of patent filings as well as Eco
and Cambridge Enterprise, the University's commercialisation office, signing
licensing agreements to jointly exploit these discoveries.
Contacts:
ECO Animal Health Group plc Marc Loomes 020 8447 8899
Spiro Financial Anthony Spiro 020 8336 6196
Cenkos Securities plc Stephen Keys 020 7397 8926
(Nominated Adviser) Elizabeth Bowman 020 7397 8928
ECO Animal Health Group plc is a leader in the development, registration and
marketing of pharmaceutical products for animals. Our products for these global
growth markets promote well-being. Our financial goals are achieved through the
careful and responsible application of science to generate value for our
shareholders.